Time filter

Source Type

Warsaw, Poland

The last decade witnessed significant improvement of myelodysplastic syndrome (MDS) therapy results. This was due to more objective criteria for histopathological diagnosis according to World Health Organization (WHO) classification and risk stratification of International Prognostic System Score (IPSS). Treatment strategies are tailored based on the therapeutic goals within each classification and prognostic risk groups and consist of the best supportive care with or without less or more intense cytoreduction. This was allowed due to the emergence of new therapies, including lenalidomide in patients with IPSS low or intermediate-low risk MDS with del(5q), and demethylating agents (azacitidine, decitabine) in the treatment of patients with intermediate-high and high risk or refractory MDS. © 2010 Via Medica. Source

Diffuse large B-cell lymphoma (DLBCL) is a group of lymphoid malignancies derived from mature peripheral B lymphocytes arising in germinal centres. It is the most commonly occurring of all lymphoma types (appr. 30%) and aggressive subtypes (appr. 80%). Its heterogeneity serve as the basis for DLBCL classification into clinical, morphological, molecular and immunohistochemical subtypes. To achieve optimal use of all available diagnostic and therapeutic resources in DLBCL patient management, the Institute of Hematology and Transfusion Medicine has developed and implemented a set of internal recommendations. As in previous publications of this kind, these recommendations refer mostly to clinical practice. For further details please consult; http://www. ihit.waw.pl/rekomendacje-ihit.html. © 2013 Via Medica. Source

Wrobel T.,Klinika Hematologii
Acta Haematologica Polonica | Year: 2010

Marginal zone lymphomas (MZL) are uncommon indolent lymphoid B-cell malignancies. Their pathogenesis is often related with infectious agents and chronic inflammation. MZLs are categorized by WHO classification into: extranodal MALT lymphomas, splenic MZL and nodal MZL. This article summarizes clinical features and therapeutic modalities of all subtypes of marginal zone lymphomas. Source

During nearly two decades there has been continuous progress in the therapy of plasma cell myeloma resulting in significant prolongation of patients' overall survival. Since 2010 the efficacy and toxicity of chemotherapy regimens including immunomodulatory drugs and proteasome inhibitors have been further optimized based on the results of numerous, large phase 3 randomized clinical trials. Moreover, intensive efforts have been made to identify novel molecular drug targets to individualize treatment and overcome resistance to existing therapies. Currently, the most promising therapeutic strategy is immunotherapy, especially development of monoclonal antibodies against CD38 antigen. © 2015 Via Medica. Source

Wrobel T.,Klinika Hematologii
Acta Haematologica Polonica | Year: 2015

Abstract Despite high curability rate 10-30% Hodgkin lymphoma patients relapse or fail to respond to the first-line therapy. Routine approaches to these patients are salvage chemotherapy and HDT/ASCT. Brentuximab vedotin, conjugated antibody antyCD30, has demonstrated significant anti-tumor activity in HL. This drug has been registered for the treatment of patients who relapse after ASCT or after multiple relapses. Recently there have been very encouraging reports of the efficacy of antiPD-1 in these patients. This article summarizes the possibilities of treatment of relapsed/refractory Hodgkin lymphoma with monoclonal antibodies. © 2015 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i Transfuzjologii. Published by Elsevier Sp. z o.o. All rights reserved. Source

Discover hidden collaborations